When Is It Too Early To Engage A CDMO?

This segment of the Outsourced Pharma Live event, “Charting A Direct Pathway From Academia To CDMOs,” explores when academic teams and emerging biotechs should begin engaging external development and manufacturing partners. Leonardo recommends approaching a CDMO once the program has a clear clinical plan, defined quality target product profile, and preliminary process strategy, while Michael discusses the additional time, resources, and opportunity costs investigators must consider before committing to commercialization. Featuring Leonardo Sibilio, Ph.D., CEO, Nexantia Biotherapeutics, and Michael Salgaller, Ph.D., Supervisor, Technology Analysis and Marketing Unit, Technology Transfer Center at NCI, NIH.